Spyre Therapeutics

131 articles about Spyre Therapeutics

• Aeglea BioTherapeutics Announces Reverse Stock Split

  9/7/2023

  Aeglea BioTherapeutics, Inc. today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023.

• Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

  8/11/2023

  Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced second quarter 2023 financial results and provided program and corporate updates.

• Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

  7/27/2023

  Aeglea BioTherapeutics, today announced that it has entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency ("ARG1-D"), to Immedica Pharma AB ("Immedica") for $15 million in upfront cash proceeds and up to $100 million in contingent milestone payments.

• Aeglea BioTherapeutics Announces Grant of Inducement Awards - June 23, 2023

  6/23/2023

  Aeglea BioTherapeutics, Inc. announced that, in connection with the acquisition of Spyre Therapeutics, Inc., a majority of the independent members of Aeglea's Board of Directors approved the grant of stock options to new employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan.

• Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

  6/22/2023

  Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a privately held biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD).

• Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results

  5/11/2023

  Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023.

• 

  Aeglea Cuts Majority of Staff Following Mixed Trial Results

  4/12/2023

  Following mixed Phase I/II data for its homocystinuria hopeful pegtarviliase, Aeglea lays off all but 10 employees and launches a sweeping strategic review.

• Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives

  4/12/2023

  Aeglea BioTherapeutics, Inc. today announced interim results from the ongoing Phase 1/2 clinical trial of pegtarviliase, a novel recombinant human enzyme engineered to reduce elevated levels of total homocysteine, for the treatment of Classical Homocystinuria.

• Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 17, 2023

  3/17/2023

  Aeglea BioTherapeutics, Inc. announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the company's 2016 Equity Incentive Plan, but under the terms of the company's 2018 Equity Inducement Plan.

• Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

  3/2/2023

  Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates.

• Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

  1/6/2023

  Aeglea BioTherapeutics today announced an update to its corporate structure.

• Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  Aeglea BioTherapeutics, Inc. announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an aggregate of 1,884,838 shares of Aeglea's common stock to Jeffrey M. Goldberg as a material inducement to his appointment as the chief executive officer of Aeglea in accordance with Rule 5635 of the Nasdaq Listing Rules.

• Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

  11/30/2022

  Aeglea BioTherapeutics, Inc. today announced the appointment of Jeffrey M. Goldberg as president, chief executive officer and member of the board of directors effective November 29, 2022.

• Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

  11/15/2022

  Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.

• Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

  11/3/2022

  Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2022 and provided program updates.

• Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment

  10/19/2022

  Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) today announced that it will host a key opinion leader (KOL) webinar on Classical Homocystinuria, and Aeglea's potential treatment and lead clinical asset pegtarviliase on Thursday, October 27, 2022 at 10:00 AM Eastern Time.

• Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

  10/4/2022

  Aeglea BioTherapeutics, Inc. today announced that dosing in the third cohort of the Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystin is underway.

• Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

  8/29/2022

  Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2.

• 

  Aeglea CEO Steps Down as Restructure Claims 25% of Workforce

  8/24/2022

  Anthony Quinn has stepped down from his role as chief executive officer and transitioned to an advisory role. Jim Kastenmayer, general counsel, will assume the post on an interim basis.

• Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

  8/24/2022

  Aeglea BioTherapeutics, Inc. today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria.